Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.42 |
| ▸ | JAK1 | P23458 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 10/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 9/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301541 | 0.84 | MAPK8 (0.41) | JAK2JAK1JAK3PTK2MAPK8 | |
| SCHEMBL3303085 | 0.84 | JAK2 (0.48) | JAK2JAK1JAK3PTK2KCNH3 | |
| SCHEMBL2144355 | 0.82 | JAK2 (0.45) | JAK2JAK1JAK3PTK2KCNH3 | |
| SCHEMBL3308940 | 0.80 | JAK2 (0.45) | JAK2JAK1JAK3PTK2KCNH3 | |
| SCHEMBL3306787 | 0.79 | JAK2 (0.42) | JAK2JAK1JAK3PTK2RORC | |
| SCHEMBL2144351 | 0.78 | JAK2 (0.43) | JAK2JAK1JAK3PTK2RORC | |
| SCHEMBL2144098 | 0.78 | JAK2 (0.43) | JAK2JAK1JAK3PTK2MAPK8 | |
| SCHEMBL3304372 | 0.78 | FAAH (0.44) | JAK2JAK1JAK3PTK2 | |
| SCHEMBL2144345 | 0.77 | JAK2 (0.42) | JAK2JAK1JAK3PTK2NTRK1 | |
| SCHEMBL14457306 | 0.77 | JAK2 (0.43) | JAK2JAK1JAK3PTK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | JAK2 26/4885JAK1 69/4885JAK3 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.